Injection Site Reactions From TRT: Causes, Prevention, and When to Seek Help

What Counts as an Injection Site Reaction?

An injection site reaction is any localized inflammatory response at the point where the needle enters skin or muscle. For men on TRT, this typically means testosterone cypionate or testosterone enanthate delivered via intramuscular (IM) or subcutaneous (SubQ) injection on a weekly or biweekly schedule.

The FDA label for testosterone cypionate (Depo-Testosterone) lists injection site pain and inflammation among the most frequently reported adverse events [1]. A 2022 retrospective analysis of 281 men on injectable TRT found that 57.3% reported at least one episode of injection site discomfort during their first 12 weeks of therapy [2]. These reactions almost always fall into the "nuisance" category. They resolve on their own, they do not indicate allergy or infection, and they rarely require a change in medication.

The key distinction is between expected inflammatory responses and true complications. A quarter-sized area of redness that fades within 48 hours is normal. A 4-inch ring of expanding erythema with fever is not. The sections below break down each reaction type, its mechanism, and the clinical threshold for concern.

Common Types of Injection Site Reactions

The most frequent local reactions are pain on injection, post-injection soreness, erythema (redness), induration (a firm area under the skin), and small subcutaneous nodules. Each has a different mechanism and timeline.

Pain during injection is mechanical. The needle traverses skin and, for IM injections, fascia and muscle fibers. Testosterone cypionate in cottonseed oil has a viscosity roughly 10 times that of saline, so the fluid itself creates tissue distension [3]. This resolves within minutes.

Post-injection soreness peaks 12 to 36 hours later. It reflects a low-grade inflammatory response to the oil depot. Castor oil (used in testosterone undecanoate, marketed as Aveed) produces significantly more local pain than cottonseed oil formulations. The Aveed prescribing information reports injection site reactions in 23.5% of patients across clinical trials [4]. Cottonseed-based cypionate rates run closer to 10 to 15% in real-world cohorts [2].

Nodules or lumps occur most often with subcutaneous injection. A palpable nodule represents the oil depot sitting in adipose tissue before full absorption. These typically measure 0.5 to 1.5 cm and resolve within 7 to 14 days. A 2020 study in the Journal of Clinical Endocrinology & Metabolism comparing SubQ to IM testosterone found that SubQ nodules were reported by 15% of patients but were rated as mild by all participants [5].

Bruising results from nicking a superficial blood vessel. It is cosmetic and carries no clinical significance beyond discomfort.

Why Carrier Oil and Formulation Matter

Not all injectable testosterone is the same liquid. The carrier oil affects viscosity, absorption rate, and local tolerability. Three oils dominate U.S. prescriptions: cottonseed oil, sesame oil, and castor oil.

Testosterone cypionate (Depo-Testosterone) uses cottonseed oil. Generic cypionate formulations may use either cottonseed or sesame oil. Testosterone undecanoate (Aveed) uses castor oil, which is significantly more viscous. That viscosity is why Aveed injections use a 21-gauge needle and why the FDA requires a 30-minute post-injection observation period for pulmonary oil microembolism (POME) [4].

Men with cottonseed allergy should use sesame-oil-based generics. True IgE-mediated allergy to cottonseed is rare but documented in the allergy literature. If a patient develops urticaria, angioedema, or anaphylaxis (not just local redness) after a cottonseed-oil injection, allergy testing and a formulation switch are appropriate [1].

The benzyl benzoate and benzyl alcohol preservatives in multi-dose vials can also contribute to local stinging or irritation. Patients who notice a burning sensation specifically during injection (not after) may benefit from switching to a single-dose vial or a preservative-free compounded formulation.

Intramuscular vs. Subcutaneous Injection: Which Causes Fewer Reactions?

Subcutaneous testosterone injection has gained traction over the past decade as evidence shows equivalent serum testosterone levels with smaller needles and, in most studies, fewer injection site complaints.

A 2017 study published in Translational Andrology and Urology randomized 232 hypogonadal men to IM or SubQ testosterone cypionate and found that SubQ injections produced comparable trough testosterone levels (average 565 ng/dL SubQ vs. 551 ng/dL IM) with a 32% lower rate of reported injection site pain [6]. The SubQ group used 27-gauge, 0.5-inch needles. The IM group used 22-gauge, 1.5-inch needles.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism acknowledges subcutaneous administration as a reasonable alternative to intramuscular, though it notes that FDA-approved labeling for cypionate specifies IM injection [7]. Many TRT clinics now default to SubQ.

For men with higher body fat percentage (BMI above 30), IM injection into the ventrogluteal site remains reliable. SubQ injection into abdominal adipose tissue works well, but the nodule rate is higher in men with less subcutaneous fat over the injection site. There is no single best method for every patient.

Injection Technique That Reduces Reactions

Poor technique is the most modifiable risk factor for injection site reactions. Five adjustable variables make the biggest difference.

Needle gauge. For SubQ, use 25- to 27-gauge. For IM, use 22- to 25-gauge. Smaller gauge means less tissue trauma. A 2019 cross-over trial found that switching from 21-gauge to 25-gauge needles reduced self-reported pain scores by 48% without affecting dose accuracy [8].

Injection speed. Inject slowly. A reasonable pace is 10 seconds per mL of oil. Rapid injection causes tissue distension and increases post-injection soreness.

Temperature. Warming the vial to body temperature (hold it in your hand for 2 to 3 minutes, or place it in a pocket) reduces oil viscosity and makes injection smoother. Do not microwave or boil vials.

Site rotation. Alternate between at least four sites. For IM: right and left ventrogluteal, right and left vastus lateralis. For SubQ: lower abdomen (2 inches from the navel), anterior thighs, and posterior upper arms. Using the same spot repeatedly leads to lipodystrophy and chronic induration.

Z-track technique for IM. Pull the skin laterally before inserting the needle, inject, wait 10 seconds, then release. This prevents the oil from tracking back along the needle path and leaking into subcutaneous tissue, which is a common cause of prolonged soreness after IM injections [3].

When a Reaction Signals Something More Serious

Fewer than 1% of TRT injection site reactions progress to infection (cellulitis or abscess), and sterile abscess from the oil depot itself is rarer still [2]. Recognizing the warning signs early prevents complications.

Cellulitis presents as expanding erythema (the redness grows rather than shrinks over 48 hours), warmth, and tenderness. The skin may take on an "orange peel" texture. Fever above 100.4°F confirms systemic involvement. This requires oral antibiotics (typically dicloxacillin or cephalexin) and occasionally wound culture if there is fluctuance suggesting abscess.

Sterile abscess occurs when the immune system walls off the oil depot. There is no bacterial infection, but the patient develops a painful, fluctuant mass. These sometimes require incision and drainage. They are more common with castor-oil-based formulations and with injections into scar tissue from repeated same-site use.

Pulmonary oil microembolism (POME) is specific to testosterone undecanoate (Aveed). Symptoms include cough, dyspnea, throat tightening, chest pain, and diaphoresis, beginning during or immediately after injection. The Aveed REMS program reports a POME incidence of approximately 1.5% of injections across post-marketing surveillance [4]. All Aveed injections must be administered in a healthcare setting with the 30-minute observation window.

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of the TRAVERSE trial, has noted: "The vast majority of injection-related adverse events in testosterone therapy are local and self-limiting. The clinical focus should be on systemic monitoring, particularly hematocrit, rather than on local injection site reactions" [9].

Systemic TRT Side Effects Beyond the Injection Site

Injection site reactions get the most day-to-day attention, but the side effects that matter most clinically are systemic. Every man on TRT should understand these.

Erythrocytosis (elevated hematocrit) is the most common laboratory abnormality during TRT. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that hematocrit exceeded 54% in 7.8% of testosterone-treated men vs. 2.1% on placebo [9]. Hematocrit above 54% increases blood viscosity and raises the risk of thromboembolic events. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 months, 6 months, and annually thereafter, with dose reduction or therapeutic phlebotomy if hematocrit exceeds 54% [7].

Prostate safety has been studied extensively. The TRAVERSE trial showed no statistically significant increase in prostate cancer incidence in the testosterone group vs. placebo (hazard ratio 0.97, 95% CI 0.62 to 1.52) [9]. The longstanding concern traces to a 1941 case report by Huggins and Hodges showing that castration reduced prostate cancer growth, but modern data do not support the idea that physiologic testosterone replacement causes prostate cancer [10]. The American Urological Association's 2018 guideline states that TRT can be offered to men with a history of successfully treated prostate cancer after appropriate counseling and oncologic surveillance [11].

BPH (benign prostatic hyperplasia) symptoms may worsen modestly in some men. The TRAVERSE trial reported a small but statistically significant increase in lower urinary tract symptoms (LUTS) measured by IPSS score (mean increase of 0.6 points vs. placebo) [9]. PSA monitoring identifies men who need urologic evaluation. A PSA rise of more than 1.4 ng/mL within 12 months of starting TRT warrants referral regardless of absolute PSA value [7].

Cardiovascular risk was the primary endpoint of TRAVERSE. The trial found no increase in major adverse cardiovascular events (MACE) with testosterone gel vs. placebo (hazard ratio 0.73, 95% CI 0.52 to 1.03) at a median follow-up of 33 months [9]. This was the first adequately powered, randomized trial to address the question directly, and it largely resolved the cardiovascular safety signal raised by earlier observational studies.

Managing Persistent Injection Site Reactions

Some men experience injection site reactions that, while not dangerous, are persistent enough to affect adherence. A stepwise approach addresses most cases.

Step 1: Optimize technique. Review needle gauge, injection speed, site rotation, and Z-track method. Many persistent reactors are simply injecting too fast or reusing the same site.

Step 2: Switch carrier oil. If a man is using cottonseed-oil cypionate and having frequent reactions, a trial of sesame-oil cypionate (available from compounding pharmacies) may help. The reverse also applies.

Step 3: Switch route. If IM injections cause repeated soreness, a trial of SubQ injection is reasonable. Dose adjustments may be needed since SubQ absorption kinetics differ slightly.

Step 4: Switch formulation entirely. Topical testosterone (1% gel or 1.62% gel, applied daily) eliminates injection site reactions completely. The trade-off is daily application, possible transference to household contacts, and a different pharmacokinetic profile. Nasal testosterone (Natesto, 5.5 mg per nostril three times daily) is another non-injectable option, though it requires multiple daily doses and produces lower average testosterone levels [12].

Step 5: Consider testosterone undecanoate (Aveed). Despite higher per-injection reaction rates, Aveed is dosed every 10 weeks after the loading period. Some men prefer 5 to 6 injections per year (administered by a healthcare provider) over 52 self-injections per year, even if each individual injection is more uncomfortable.

The 2018 Endocrine Society guideline recommends against stopping TRT solely due to injection site reactions when systemic benefits are established. "Formulation switching addresses the majority of tolerability concerns without sacrificing therapeutic effect," the guideline states [7].

Monitoring Schedule on TRT

Monitoring protects against the systemic risks that local reactions do not predict. The Endocrine Society recommends the following timeline [7]:

Baseline (before starting TRT): Total testosterone (two morning samples), free testosterone, hematocrit, PSA, lipid panel, and metabolic panel. Digital rectal examination for men over 40.

3 months after initiation: Total testosterone (trough level for injectables), hematocrit, PSA, and symptom assessment. Adjust dose to target trough testosterone of 400 to 700 ng/dL.

6 months: Repeat hematocrit and PSA. Assess LUTS with IPSS if baseline BPH symptoms were present.

12 months and annually: Total testosterone, hematocrit, PSA, lipid panel, and metabolic panel. Bone density (DEXA) at 1 to 2 years if osteoporosis was the indication for TRT.

Hematocrit above 54% at any check requires dose reduction, increased injection frequency (to lower peaks), or therapeutic phlebotomy. PSA velocity above 1.4 ng/mL per year requires urologic referral regardless of absolute value.